{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: The guideline states, \"No treatments improve pregnancy outcomes or reduce bile acid concentrations\" and \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\"  \n\n2. **Different management plan** - Adjust fetal surveillance strategy: Reduce frequency of growth scans and CTGs unless bile acids ≥100 µmol/L, as these do not predict or prevent stillbirth.  \n   Reason: The guideline explicitly states, \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\"  \n\n3. **Additional information needed** - Document baseline bile acid levels from booking bloods to establish a reference for comparison.  \n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \n\n### Somewhat Important Recommendations\n1. **Improved patient advice** - Provide clearer counseling on the lack of benefit of UDCA for fetal outcomes and its role only in symptom relief.  \n   Reason: The guideline emphasizes that UDCA does not improve perinatal outcomes but may reduce maternal itch.  \n\n2. **Additional information needed** - Screen for gestational diabetes and pre-eclampsia, as women with ICP have a higher chance of these conditions.  \n   Reason: The guideline states, \"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\"  \n\n3. **Different management plan** - Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.  \n   Reason: The guideline states, \"Dietary fat absorption is impaired in women with ICP, but routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\"  \n\n### Less Important Recommendations\n1. **Improved patient advice** - Offer links to ICP Support and RCOG resources for additional patient education.  \n   Reason: The guideline lists these as useful links for women and families.  \n\n2. **Additional information needed** - Document postnatal follow-up plans to confirm resolution of ICP.  \n   Reason: The guideline recommends follow-up at least 4 weeks postpartum to confirm resolution.  \n\n### Unimportant Recommendations\n1. **Improved patient advice** - Consider mentioning the small increased risk of future hepatobiliary or immune-mediated diseases.  \n   Reason: The guideline notes this as a long-term consideration but does not mandate discussion.  \n\n### Summary of Critical Changes Needed:\n- **Stop routine UDCA** unless for symptomatic relief.  \n- **Reduce unnecessary fetal surveillance** (growth scans/CTGs) unless bile acids ≥100 µmol/L.  \n- **Add screening for gestational diabetes/pre-eclampsia**.  \n- **Clarify counseling** on UDCA’s limited role.  \n\nThese changes align the note with the guideline’s emphasis on avoiding over-investigation/unproven treatments while focusing on risk stratification (bile acids ≥100 µmol/L) and comorbid condition screening.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 57 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 3488,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if pruritus is severe, after discussing its limited role in perinatal outcomes with patient.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered as it does not improve perinatal outcomes\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Perform CTGs and growth scans only if bile acids ≥100 µmol/L\",\n      \"context\": \"Guideline states fetal surveillance does not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends establishing baseline measurements for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Gap: no screening for gestational diabetes or pre-eclampsia\",\n      \"suggestedText\": \"Add screening for gestational diabetes and pre-eclampsia to management plan\",\n      \"context\": \"Women with ICP have higher risk of these conditions per guideline\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, including clarification that UDCA only helps with symptoms and does not reduce stillbirth risk\",\n      \"context\": \"Guideline emphasizes need for clear counseling about UDCA's limited role\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Missing: postnatal follow-up plan\",\n      \"suggestedText\": \"Add plan for postnatal follow-up at 4 weeks to confirm resolution of ICP\",\n      \"context\": \"Guideline recommends postnatal follow-up to confirm resolution\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Full blood count and clotting screen (due to potential risk of coagulopathy).\",\n      \"suggestedText\": \"Consider clotting screen only if steatorrhea or symptoms of coagulopathy present\",\n      \"context\": \"Guideline does not recommend routine vitamin K or coagulation testing unless symptoms present\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-13T16-45-12",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \\n   Reason: The guideline states, \\\"No treatments improve pregnancy outcomes or reduce bile acid concentrations\\\" and \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\\\"  \\n\\n2. **Different management plan** - Adjust fetal surveillance strategy: Reduce frequency of growth scans and CTGs unless bile acids ≥100 µmol/L, as these do not predict or prevent stillbirth.  \\n   Reason: The guideline explicitly states, \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\\\"  \\n\\n3. **Additional information needed** - Document baseline bile acid levels from booking bloods to establish a reference for comparison.  \\n   Reason: The guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \\n\\n### Somewhat Important Recommendations\\n1. **Improved patient advice** - Provide clearer counseling on the lack of benefit of UDCA for fetal outcomes and its role only in symptom relief.  \\n   Reason: The guideline emphasizes that UDCA does not improve perinatal outcomes but may reduce maternal itch.  \\n\\n2. **Additional information needed** - Screen for gestational diabetes and pre-eclampsia, as women with ICP have a higher chance of these conditions.  \\n   Reason: The guideline states, \\\"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\\\"  \\n\\n3. **Different management plan** - Avoid routine vitamin K unless steatorrhea or abnormal coagulation is present.  \\n   Reason: The guideline states, \\\"Dietary fat absorption is impaired in women with ICP, but routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\\\"  \\n\\n### Less Important Recommendations\\n1. **Improved patient advice** - Offer links to ICP Support and RCOG resources for additional patient education.  \\n   Reason: The guideline lists these as useful links for women and families.  \\n\\n2. **Additional information needed** - Document postnatal follow-up plans to confirm resolution of ICP.  \\n   Reason: The guideline recommends follow-up at least 4 weeks postpartum to confirm resolution.  \\n\\n### Unimportant Recommendations\\n1. **Improved patient advice** - Consider mentioning the small increased risk of future hepatobiliary or immune-mediated diseases.  \\n   Reason: The guideline notes this as a long-term consideration but does not mandate discussion.  \\n\\n### Summary of Critical Changes Needed:\\n- **Stop routine UDCA** unless for symptomatic relief.  \\n- **Reduce unnecessary fetal surveillance** (growth scans/CTGs) unless bile acids ≥100 µmol/L.  \\n- **Add screening for gestational diabetes/pre-eclampsia**.  \\n- **Clarify counseling** on UDCA’s limited role.  \\n\\nThese changes align the note with the guideline’s emphasis on avoiding over-investigation/unproven treatments while focusing on risk stratification (bile acids ≥100 µmol/L) and comorbid condition screening.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 57 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 3488,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if pruritus is severe, after discussing its limited role in perinatal outcomes with patient.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered as it does not improve perinatal outcomes\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Perform CTGs and growth scans only if bile acids ≥100 µmol/L\",\n      \"context\": \"Guideline states fetal surveillance does not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends establishing baseline measurements for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Gap: no screening for gestational diabetes or pre-eclampsia\",\n      \"suggestedText\": \"Add screening for gestational diabetes and pre-eclampsia to management plan\",\n      \"context\": \"Women with ICP have higher risk of these conditions per guideline\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Discussed nature of obstetric cholestasis, including clarification that UDCA only helps with symptoms and does not reduce stillbirth risk\",\n      \"context\": \"Guideline emphasizes need for clear counseling about UDCA's limited role\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Missing: postnatal follow-up plan\",\n      \"suggestedText\": \"Add plan for postnatal follow-up at 4 weeks to confirm resolution of ICP\",\n      \"context\": \"Guideline recommends postnatal follow-up to confirm resolution\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Full blood count and clotting screen (due to potential risk of coagulopathy).\",\n      \"suggestedText\": \"Consider clotting screen only if steatorrhea or symptoms of coagulopathy present\",\n      \"context\": \"Guideline does not recommend routine vitamin K or coagulation testing unless symptoms present\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1881\nCompletion tokens: 800\nTotal tokens: 2681\nEstimated cost: $0.001341",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1881,
    "completion_tokens": 800,
    "total_tokens": 2681,
    "estimated_cost_usd": 0.0013405000000000001
  }
}